Cann Group Ltd (ASX: CAN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cann Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar. Market Cap $115.31 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 351.36 million
Earnings per share -0.075
Dividend per share N/A
Year To Date Return 8.62%
Earnings Yield N/A
Franking N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cann Group Ltd (ASX: CAN)
Latest News
Share Gainers
Why Argosy Minerals, Cann, OZ Minerals, and PointsBet shares are pushing higher
Cannabis Shares
Why is the Cann share price smoking out the ASX by 20% today
Cannabis Shares
Remember when ASX cannabis shares were smoking hot? Where are they now?
Cannabis Shares
ASX cannabis shares in spotlight amid COVID prevention research
Share Gainers
Beaten up ASX cannabis shares showing signs of life
Cannabis Shares
ASX cannabis shares eyeing $63 billion in legal global sales
Share Fallers
Why a2 Milk, Cann, Flight Centre, & GPT shares are tumbling lower
Capital Raising
Cann (ASX:CAN) share price crashes 14% after announcing another capital raising
CAN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cann Group Ltd
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the company; the development and manufacture (via third party arrangements) of finished product formulations; and the pursuit and execution of various supply and offtake agreements with third parties.
CAN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Jul 2022 | $0.32 | $-0.01 | -3.13% | 1,017,163 | $0.33 | $0.35 | $0.31 |
| 01 Jul 2022 | $0.32 | $0.05 | 18.18% | 1,508,772 | $0.30 | $0.34 | $0.29 |
| 30 Jun 2022 | $0.28 | $0.05 | 21.74% | 2,366,181 | $0.25 | $0.30 | $0.25 |
| 29 Jun 2022 | $0.23 | $-0.01 | -4.17% | 1,002,849 | $0.24 | $0.24 | $0.23 |
| 28 Jun 2022 | $0.24 | $0.00 | 0.00% | 417,896 | $0.24 | $0.25 | $0.24 |
| 27 Jun 2022 | $0.24 | $-0.01 | -4.00% | 475,632 | $0.25 | $0.25 | $0.24 |
| 24 Jun 2022 | $0.25 | $0.01 | 4.17% | 431,426 | $0.25 | $0.26 | $0.25 |
| 23 Jun 2022 | $0.24 | $-0.01 | -4.00% | 431,842 | $0.25 | $0.26 | $0.24 |
| 22 Jun 2022 | $0.25 | $0.01 | 4.08% | 670,652 | $0.25 | $0.27 | $0.25 |
| 21 Jun 2022 | $0.25 | $0.00 | 0.00% | 709,958 | $0.24 | $0.26 | $0.24 |
| 20 Jun 2022 | $0.25 | $-0.03 | -11.11% | 1,197,699 | $0.27 | $0.28 | $0.25 |
| 17 Jun 2022 | $0.27 | $-0.01 | -3.57% | 196,157 | $0.28 | $0.28 | $0.27 |
| 16 Jun 2022 | $0.28 | $0.01 | 3.64% | 479,757 | $0.27 | $0.28 | $0.27 |
| 15 Jun 2022 | $0.28 | $0.00 | 0.00% | 200,109 | $0.28 | $0.28 | $0.27 |
| 14 Jun 2022 | $0.28 | $-0.02 | -6.78% | 1,219,457 | $0.28 | $0.29 | $0.27 |
| 10 Jun 2022 | $0.30 | $-0.01 | -3.33% | 887,777 | $0.30 | $0.30 | $0.29 |
| 09 Jun 2022 | $0.30 | $-0.01 | -3.23% | 228,032 | $0.31 | $0.31 | $0.30 |
| 08 Jun 2022 | $0.31 | $-0.01 | -3.17% | 124,108 | $0.32 | $0.32 | $0.31 |
| 07 Jun 2022 | $0.32 | $-0.01 | -3.08% | 66,904 | $0.33 | $0.33 | $0.31 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 07 Sep 2021 | Douglas (Doug) Rathbone | Buy | 363 | $100,000 | Placement. |
| 07 Sep 2021 | Allan McCallum | Buy | 545 | $150,000 | Placement. |
| 07 Sep 2021 | John Sharman | Buy | 72 | $20,000 | Placement. |
| 07 Sep 2021 | Philip Jacobsen | Buy | 2 | $750,000 | Placement. |
| 07 Sep 2021 | Geoffrey(Geoff) Pearce | Buy | 181 | $50,000 | Placement. |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Douglas (Doug) John Rathbone | Non-Executive Director | Mar 2015 | Mr Rathbone is an experienced public company director and is a former Board member of the FERNZ Corporation and the CSIRO. He is Chairman of the Rathbone Wine Group and Chairman since 1 April 2018, Go Resources, Queenscliff Harbour Pty Ltd and AgBiTech. He is also a former member of the RABO Bank Advisory Board, an Honorary Life Governor of the Royal Children's Hospital and a former Director of the Burnett Centre for Medical Research. Doug brings to the Board experienced management and corporate governance skills together with a passion to grow the business having successfully transformed Nufarm to become one of the world's leading crop protection and seed companies with an global footprint. He is also member of Risk and Capital Committees. |
| Mr Allan D McCallum | Non-Executive ChairmanNon-Executive Director | Jan 2015 | Mr McCallum has broad experience as a public company director in agribusiness and healthcare and have experience in strategy development and implementation and mergers and acquisitions. He is also member of Risk Committee and chairman of Capital Committees. |
| Mr John Stewart Sharman | Non-Executive Director | Apr 2021 | Mr Sharman has an international business experience as a Managing Director, CEO, CFO and non-executive director with public and private companies, including several ASX listed entities. He has an understanding of the medical manufacturing industry as well as the pharmaceutical and nutraceutical sectors. He has led businesses with operations in Australia, the UK, Europe, Asia and the USA, building distribution, sales, marketing and manufacturing networks both locally and internationally. Mr Sharman is currently the CEO of Universal Biosensors Inc (ASX:UBI). Prior to that he served 10 years as CEO of Medical Developments International (ASX:MVP). Previous roles included Managing Director of CVC Venture Managers (private equity managers), Managing Director of Vita Life Sciences (ASX:VSC) and Cyclopharm (ASX:CYC), as well as roles at PriceWaterhouseCoopers, National Australia Bank and KPMG in both London and Melbourne. |
| Ms Jennifer (Jenni) Pilcher | Non-Executive Director | Sep 2020 | Ms Pilcher has senior executive experience in the medical and biotechnology sectors and is currently the Chief Financial Officer and Company Secretary of Mach7 Technologies (ASX:M7T). She has previously held executive roles with Alchemia Limited (ASX:ACL) and Mesoblast Limited (ASX:MSB). |
| Mr Peter Crock | Chief Executive Officer | - | |
| Ms Geraldine Farrell | Company Secretary | Dec 2019 | - |
| Peter Crock | Chief Executive Officer | - | |
| Greg Bullock | Chief Financial Officer | - | |
| Shane Duncan | Chief Operating Officer | - | |
| Geoff Aldred | Chief Projects & Information Officer | - | |
| Geraldine Farrell | Company Secretary | - |
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| National Nominees Limited | 9,202,765 | 2.96% |
| Mr Philip Jacobsen & Mrs Maxine Jacobsen | 6,319,518 | 2.03% |
| Flag Capital Pty Ltd | 6,114,881 | 1.97% |
| Mullacam Pty Ltd | 5,155,000 | 1.66% |
| Supernova Fund Pty Ltd | 3,590,909 | 1.16% |
| Citicorp Nominees Pty Limited | 2,987,457 | 0.96% |
| HSBC Custody Nominees (Australia) Limited | 2,703,456 | 0.87% |
| Harvest One Cannabis Inc | 2,248,615 | 0.72% |
| Invia Custodian Pty Limited | 2,225,395 | 0.72% |
| Hardmail Pty Ltd | 1,931,852 | 0.62% |
| Ms Samira Oliveira Vescovi | 1,800,000 | 0.58% |
| Commonwealth Scientific And | 1,675,533 | 0.54% |
| Industrial Research Organisation | 1,525,000 | 0.49% |
| BNP Paribas Nominees Pty Ltd | 1,350,000 | 0.43% |
| Australian Businesspoint Pty Ltd | 1,250,000 | 0.40% |
| Mr Raymond Thomas Hobson & Mrs Rhonda Ellen Hobson | 1,200,000 | 0.39% |
| Ms Lifang Hao | 1,200,000 | 0.39% |
| Egea Pty Ltd | 1,149,050 | 0.37% |
| Estelville Nominees Proprietary Limited | 1,127,148 | 0.36% |
| BNP Paribas Nominees Pty Ltd Six Sis Ltd | 1,062,000 | 0.34% |